|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Microfluidizer Á¾ÇÕÄ«´Ù·Î±× |
Phone |
|
|
  ´ëÇ¥ÀüÈ |
1577-7956   |
  º»     »ç |
031-457-9187   |
  ´ë     Àü |
042-932-1265 |
|
|
Web Site Visitors |
|
|
  Today |
795     |
  Yesterday |
897     |
  Since 2006 |
1,916,511     |
|
|
|
|
¿µÁøÄÚÆÛ·¹ÀÌ¼Ç Á¾ÇÕÄ«´Ù·Î±× |
|
|
2022³â 9¿ù 16ÀÏ ¹Ì±¹ Microfluidics »ç´Â Â÷¼¼´ë mRNA ¹ÙÀÌ¿À ÀǾàÇ° °³¹ß·Î À¯¸íÇÑ ¹Ì±¹ HDT Bio »ç¿Í °øµ¿À¸·Î
Joint Webinar ¸¦ °³ÃÖÇÏ¿´½À´Ï´Ù.
¹ßÇ¥ÀÚ´Â HDT Bio »çÀÇ Dr. Darrick Carter ·Î¼ mRNA ±â¹ÝÀÇ ¹ÙÀÌ¿À ÀǾàÇ° °³¹ßÀ» À§ÇÑ ±Ù¿ø ±â¼úÀÎ
LION¢â RNA Delivery System °³¹ßÀڷμ À̹ø webinar ¸¦ ÅëÇØ Â÷¼¼´ë RNA Technology ¿Í Delivery System ¿¡
°üÇØ ±í°í ´Ù¾çÇÑ Áö½ÄÀ» ¹ßÇ¥ÇÏ¿´½À´Ï´Ù.
|
      LION¢â RNA Delivery System |
¿©±â¼´Â ÀÌÇظ¦ µ½±â À§ÇØ ÀÚ¸·À» Æ÷ÇÔÇÏ´Â webinar ¹ßÇ¥ µ¿¿µ»óÀ» ¼Ò°³ÇØ µå¸®°í ÀÖ½À´Ï´Ù.
ÁÖ     Á¦ : |
A Scalable Solution for Next-Generation RNA Technology and Delivery |
|
¹ß Ç¥ ÀÚ : |
Dr. Darrick Carter (HDT Bio) |
|
¹ßÇ¥³»¿ë : |
¡Ü |
Addressing stability issues and dosing coordination learned whilst delivering the newly developed saRNA Covid-19 vaccine |
|
¡Ü |
How to overcome drug delivery challenges |
|
¡Ü |
Future opportunities with RNA technology in the area of infectious disease and cancer therapeutics |
|
¡Ü |
How to replicate results from research & development to production scale while maintaining consistent, repeatable results |
|
¡Ü |
cGMP considerations to bear in mind when selecting equipment. |
|
|
|
|
|
|